

Alessandro Gozzetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7549200/publications.pdf>

Version: 2024-02-01

231
papers

4,637
citations

117453

34
h-index

123241

61
g-index

236
all docs

236
docs citations

236
times ranked

5206
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 2434-2441.	0.8	329
2	Effect of a p210 multi-peptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. <i>Lancet, The</i> , 2005, 365, 657-662.	6.3	221
3	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	0.6	193
4	Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2273-2281.	0.8	153
5	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , 2020, 136, 3033-3040.	0.6	146
6	The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. <i>British Journal of Haematology</i> , 2009, 146, 64-75.	1.2	136
7	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.	2.8	126
8	Fluorescence in situ hybridization: Uses and limitations. <i>Seminars in Hematology</i> , 2000, 37, 320-333.	1.8	120
9	Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay. <i>Neuroradiology</i> , 2008, 50, 665-674.	1.1	116
10	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012, 120, 761-767.	0.6	110
11	Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients. <i>Cancer</i> , 2012, 118, 1574-1584.	2.0	102
12	Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1993, 4, 575-578.	0.6	84
13	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. <i>Frontiers in Oncology</i> , 2018, 8, 194.	1.3	84
14	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	2.0	83
15	Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. <i>British Journal of Haematology</i> , 2008, 142, 529-537.	1.2	78
16	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 633-643.	1.5	67
17	Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 8002-8002.	0.8	67
18	Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. <i>Annals of Oncology</i> , 2011, 22, 1628-1635.	0.6	65

#	ARTICLE	IF	CITATIONS
19	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. <i>Blood</i> , 2009, 114, 4939-4943.	0.6	62
20	Fluorescence in situ hybridization: Uses and limitations. <i>Seminars in Hematology</i> , 2000, 37, 320-333.	1.8	62
21	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e401-e419.	0.2	61
22	Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. <i>Blood Cancer Journal</i> , 2013, 3, e162-e162.	2.8	56
23	Adult Lymphoblastic Lymphoma: Clinical Features and Prognostic Factors in 53 Patients. <i>Leukemia and Lymphoma</i> , 1996, 23, 577-582.	0.6	55
24	High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. <i>Bone Marrow Transplantation</i> , 1998, 22, 27-32.	1.3	54
25	Therapeutic Advancements in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2014, 4, 241.	1.3	53
26	Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol. <i>Frontiers in Medicine</i> , 2020, 7, 466.	1.2	53
27	Insights into JAK2-V617F mutation in CML. <i>Lancet Oncology</i> , The, 2007, 8, 864-866.	5.1	50
28	Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. <i>Genes Chromosomes and Cancer</i> , 2004, 40, 179-189.	1.5	46
29	Bortezomib and thalidomide induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. <i>American Journal of Hematology</i> , 2014, 89, 1085-1091.	2.0	45
30	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	2.0	45
31	Detection of translocations affecting the BCL6 locus in B cell non-Hodgkin's lymphoma by interphase fluorescence in situ hybridization. <i>Leukemia</i> , 2001, 15, 1475-1484.	3.3	42
32	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	1.2	41
33	The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype. <i>Hematological Oncology</i> , 2007, 25, 38-43.	0.8	37
34	Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. <i>Hematological Oncology</i> , 2008, 26, 247-251.	0.8	36
35	Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 145-150.	1.4	36
36	Novel Agents in CNS Myeloma Treatment. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2014, 14, 23-27.	0.5	34

#	ARTICLE	IF	CITATIONS
37	CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. <i>Haematologica</i> , 2002, 87, 1135-40.	1.7	34
38	Human Cytotoxic T Lymphocytes Form Dysfunctional Immune Synapses with B Cells Characterized by Non-Polarized Lytic Granule Release. <i>Cell Reports</i> , 2016, 15, 9-18.	2.9	32
39	Thalidomide+dexamethasone as upfront therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. <i>European Journal of Haematology</i> , 2010, 84, 484-492.	1.1	31
40	The Role of Tumor-Associated Macrophages in Hematologic Malignancies. <i>Cancers</i> , 2021, 13, 3597.	1.7	31
41	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	0.6	30
42	Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. <i>Haematologica</i> , 2002, 87, 934-42.	1.7	30
43	Cytokeratin-positive interstitial cell neoplasm: a case report and classification issues. <i>Histopathology</i> , 2003, 43, 491-494.	1.6	29
44	Characterization of Ph-negative abnormal clones emerging during imatinib therapy. <i>Cancer</i> , 2007, 109, 2466-2472.	2.0	29
45	Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. <i>Leukemia Research</i> , 2015, 39, 1066-1070.	0.4	29
46	Fludarabine in patients with advanced and/or resistant B-cell chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 1993, 51, 93-97.	1.1	28
47	Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. <i>Cancer Genetics and Cytogenetics</i> , 2010, 199, 76-80.	1.0	28
48	Flow Cytometry Assessment of CD26 + Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 294-299.	0.7	28
49	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	3.3	28
50	Monitoring Bulky Mediastinal Disease with Gallium-67, CT-Scan and Magnetic Resonance Imaging in Hodgkin's Disease and High-Grade Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1996, 22, 131-135.	0.6	27
51	Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 600-603.	12.5	26
52	Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. <i>Oncotarget</i> , 2016, 7, 72311-72321.	0.8	26
53	Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. <i>Haematologica</i> , 2007, 92, 564-565.	1.7	25
54	Selection and Transplantation of Autologous Hematopoietic CD34+Cells for Patients with Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1997, 26, 1-11.	0.6	24

#	ARTICLE	IF	CITATIONS
55	Hematogenous extramedullary relapse in multiple myeloma – a multicenter retrospective study in 127 patients. <i>American Journal of Hematology</i> , 2019, 94, 1132-1140.	2.0	24
56	Activity of Rituximab Monotherapy in Refractory Splenic Marginal Zone Lymphoma Complicated with Autoimmune Hemolytic Anemia. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 496-499.	1.4	23
57	The Effects of Zoledronic Acid on Serum Lipids in Multiple Myeloma Patients. <i>Calcified Tissue International</i> , 2008, 82, 258-262.	1.5	23
58	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	0.6	23
59	Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study. <i>Blood</i> , 2006, 108, 800-800.	0.6	23
60	Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection. <i>Haematologica</i> , 2014, 99, e235-e237.	1.7	22
61	The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19. <i>Leukemia</i> , 2020, 34, 2815-2816.	3.3	22
62	CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. <i>Leukemia</i> , 2008, 22, 426-428.	3.3	21
63	Characteristics and outcomes of patients with multiple myeloma aged 21–40 years versus 41–60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891.	1.2	21
64	Anti CD38 monoclonal antibodies for multiple myeloma treatment. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-9.	1.4	21
65	Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 529-535.	2.0	20
66	Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. <i>The Hematology Journal</i> , 2004, 5, 472-474.	2.0	17
67	Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 171.	2.1	17
68	Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. <i>Leukemia</i> , 2006, 20, 142-143.	3.3	16
69	Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 68-72.	0.2	16
70	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019, 11, 896.	1.7	16
71	Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2007, 139, 90-93.	1.2	15
72	Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI). <i>European Journal of Haematology</i> , 2003, 71, 313-314.	1.1	14

#	ARTICLE	IF	CITATIONS
73	Multiple Myeloma Involving the Cavernous Sinus: A Report of 3 Cases and Response to Bortezomib. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 376-378.	1.4	14
74	EBV Reactivation and Chromosomal Polysomies: <i>Euphorbia tirucalli</i> as a Possible Cofactor in Endemic Burkitt Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-11.	0.6	14
75	Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia. <i>British Journal of Haematology</i> , 2012, 157, 497-498.	1.2	14
76	Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2000-2002.	0.2	14
77	Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia. <i>Hematology</i> , 2005, 10, 383-386.	0.7	13
78	Unusual Discordant Responses in Two Multiple Myeloma Patients during Bortezomib Treatment. <i>Onkologie</i> , 2008, 31, 45-47.	1.1	13
79	Evaluation of residual CD34 ⁺ Ph ⁺ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. <i>Cancer</i> , 2012, 118, 5265-5269.	2.0	13
80	Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice. <i>Journal of Personalized Medicine</i> , 2020, 10, 120.	1.1	13
81	Massive intravascular hemolysis: a fatal complication of <i>Clostridium perfringens</i> septicemia in a patient with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2005, 46, 793-793.	0.6	12
82	Myelodysplasia presenting as thoracic spinal epidural extramedullary hematopoiesis: a rare treatable cause of spinal cord myelopathy. <i>Skeletal Radiology</i> , 2012, 41, 611-614.	1.2	12
83	Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia. <i>Leukemia Research</i> , 2014, 38, 891-895.	0.4	12
84	Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2017, 130, 2006-2017.	0.6	12
85	The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma. <i>Haematologica</i> , 2006, 91, 1720-1.	1.7	12
86	Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, 877-884.	2.0	12
87	Second Generation Proteasome Inhibitors in Multiple Myeloma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 920-926.	0.9	11
88	Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 570187.	1.3	11
89	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11
90	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304.	0.2	11

#	ARTICLE	IF	CITATIONS
91	Allogeneic bone marrow transplantation for the treatment of multiple myeloma: An overview of published reports. <i>Stem Cells</i> , 1995, 13, 126-131.	1.4	10
92	Thrombotic Thrombocytopenic Purpura Secondary to an Occult Adenocarcinoma. <i>Oncologist</i> , 2005, 10, 299-300.	1.9	10
93	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide+dexamethasone incorporated into double autologous transplantation. <i>Annals of Hematology</i> , 2013, 92, 1271-1280.	0.8	10
94	Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up. <i>Hematological Oncology</i> , 2013, 31, 213-217.	0.8	10
95	Promyelocytic Blast Crisis of Chronic Myelogenous Leukemia during Imatinib Treatment. <i>Acta Haematologica</i> , 2007, 117, 236-237.	0.7	9
96	Plasmacytoma of the skull. <i>European Journal of Haematology</i> , 2012, 88, 369-369.	1.1	9
97	Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia. <i>Cancer</i> , 2014, 120, 451-452.	2.0	9
98	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574.	0.8	9
99	Identification of novel cryptic translocations involving IGH in B-cell non-Hodgkin's lymphomas. <i>Cancer Research</i> , 2002, 62, 5523-7.	0.4	9
100	Molecular Cytogenetic Analysis of B-CLL Patients with Aggressive Disease. <i>Hematology</i> , 2004, 9, 383-385.	0.7	8
101	Extramedullary myeloma relapses. <i>Annals of Hematology</i> , 2012, 91, 1511-1512.	0.8	8
102	Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2014, 55, 781-785.	0.6	8
103	Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. <i>Tumori</i> , 2013, 99, e193-202.	0.6	8
104	The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma. <i>Best Practice and Research: Clinical Haematology</i> , 1995, 8, 795-813.	1.1	7
105	A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement. <i>Cancer Genetics and Cytogenetics</i> , 2003, 144, 177-178.	1.0	7
106	Increased serum lactate dehydrogenase isoenzymes in Ph-negative chronic myeloproliferative diseases: A metabolic adaptation?. <i>Hematology</i> , 2006, 11, 239-244.	0.7	7
107	Reply to Rituximab activity in CD20 positive multiple myeloma. <i>Leukemia</i> , 2007, 21, 1842-1843.	3.3	7
108	A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report. <i>Leukemia Research</i> , 2011, 35, e206-e208.	0.4	7

#	ARTICLE	IF	CITATIONS
109	Extramedullary multifocal plasmacytoma relapse in multiple myeloma. <i>Leukemia Research</i> , 2012, 36, e34-e36.	0.4	7
110	Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. <i>Annals of Hematology</i> , 2017, 96, 1693-1698.	0.8	7
111	Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial. <i>Blood</i> , 2020, 136, 44-45.	0.6	7
112	Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 886-895.	0.9	7
113	A novel t(6;7)(p24;q21) in a chronic myelocytic leukemia in complete cytogenetic remission after therapy with imatinib mesylate. <i>Cancer Genetics and Cytogenetics</i> , 2004, 148, 152-154.	1.0	6
114	Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5qâ€•deletion. <i>British Journal of Haematology</i> , 2010, 148, 483-484.	1.2	6
115	Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes With Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients With Chronic Lymphocytic Leukemia From Senegal. <i>American Journal of Clinical Pathology</i> , 2017, 148, 545-554.	0.4	6
116	BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.. <i>Blood</i> , 2009, 114, 648-648.	0.6	6
117	Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients. <i>Blood</i> , 2010, 116, 3562-3562.	0.6	6
118	Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?. <i>Blood</i> , 2013, 122, 1482-1482.	0.6	6
119	Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Frontiers in Oncology</i> , 2022, 12, 835563.	1.3	6
120	Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
121	The Use of FluorescenceIn SituHybridization (FISH) in Chronic Lymphocytic Leukemia (CLL). <i>Hematology</i> , 2004, 9, 11-15.	0.7	5
122	Concomitant t(4;11) and t(1;19) in a patient with biphenotypic acute leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 81-82.	1.0	5
123	Plasma Cell Leukemia â€œ Facts and Controversies: More Questions than Answers?. <i>Clinical Hematology International</i> , 2020, 2, 133.	0.7	5
124	Trisomy 12 and t(14;22)(q32;q11) in a Patient with B-cell Chronic Lymphocytic Leukemia. <i>Hematology</i> , 2004, 9, 405-407.	0.7	4
125	Reply to â€œRituximab activity in CD20-positive multiple myelomaâ€™. <i>Leukemia</i> , 2008, 22, 1083-1083.	3.3	4
126	Concomitant chronic myeloid leukemia and chronic lymphocytic leukemia: a different clonal origin shown by molecular cytogenetics. <i>Cancer Genetics and Cytogenetics</i> , 2008, 180, 83-84.	1.0	4

#	ARTICLE	IF	CITATIONS
127	Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 353-360.	0.2	4
128	First reported case of secondary mixed phenotype acute leukemia after multiple myeloma. <i>American Journal of Blood Research</i> , 2021, 11, 123-131.	0.6	4
129	Combined Use of Growth Factors to Stimulate the Proliferation of Hematopoietic Progenitor Cells after Autologous Bone Marrow Transplantation for Lymphoma Patients. <i>Acta Haematologica</i> , 1996, 95, 164-170.	0.7	3
130	Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis. <i>Leukemia and Lymphoma</i> , 2005, 46, 1837-1838.	0.6	3
131	Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen (GO-FLAI) as First-Line Induction Therapy plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients. <i>Acta Haematologica</i> , 2007, 118, 7-9.	0.7	3
132	Trisomy 8 in chronic lymphocytic leukemia: a report of two cases. <i>Cancer Genetics and Cytogenetics</i> , 2007, 175, 175-176.	1.0	3
133	Deletion 9q in a patient with concomitant myelodysplasia and non-Hodgkin lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2007, 175, 177.	1.0	3
134	Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma. <i>Leukemia Research</i> , 2010, 34, e288-e289.	0.4	3
135	Lenalidomide maintenance in myeloma. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 605-605.	12.5	3
136	Sixth nerve and superior division of third nerve palsy due to intracranial extension of multiple myeloma. A diagnostic challenge and differential diagnosis. <i>Neurological Sciences</i> , 2018, 39, 593-594.	0.9	3
137	Daratumumab efficacy in extramedullary orbital myeloma. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3652-3653.	0.2	3
138	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3
139	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. <i>Blood</i> , 2018, 132, 4452-4452.	0.6	3
140	Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 605-605.	0.6	3
141	Autologous Peripheral Blood Stem-Cell (PBSC) Collection Is Not Impaired by Bortezomib-Thalidomide-Dexamethasone (VTD) Induction Therapy in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 317-317.	0.6	3
142	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. <i>Blood</i> , 2016, 128, 2038-2038.	0.6	3
143	Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 1040-1045.	0.9	3
144	A BRAF-Negative Classic Hairy Cell Leukemia Patient with LongLasting Complete Remission after Rituximab and Pentostatin. <i>Turkish Journal of Haematology</i> , 2020, 37, 286-287.	0.2	3

#	ARTICLE	IF	CITATIONS
145	Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes. <i>Leukemia and Lymphoma</i> , 2022, 63, 984-990.	0.6	3
146	Drug resistance and minimal residual disease in multiple myeloma. <i>Cancer Drug Resistance (Alhambra)</i> , 2021, 10, 100000.	0.9	3
147	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	1.7	3
148	An unusual presentation of chronic B-cell lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2004, 124, 129-129.	1.2	2
149	Cutaneous myeloma and bortezomib. <i>Annals of Hematology</i> , 2009, 88, 1045-1045.	0.8	2
150	Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012041.	0.5	2
151	Central nervous system multiple myeloma. <i>Annals of Hematology</i> , 2016, 95, 519-520.	0.8	2
152	Intravenous (<sc>IV</sc>) bortezomib infusion after non-€response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to <sc>IV</sc> bortezomib?. <i>British Journal of Haematology</i> , 2017, 177, 144-147.	1.2	2
153	Low-€level <i><sc>TP</sc>>53</i> mutational load antecedes clonal expansion in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 657-659.	1.2	2
154	Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study. <i>Medicina (Lithuania)</i> , 2021, 57, 900.	0.8	2
155	Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results. <i>Blood</i> , 2008, 112, 2768-2768.	0.6	2
156	Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.. <i>Blood</i> , 2010, 116, 3413-3413.	0.6	2
157	Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study. <i>Blood</i> , 2014, 124, 4734-4734.	0.6	2
158	LDH Levels Predict Progression-Free Survival in Treatment-Na-€ve Patients with Trisomy 12 Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3211-3211.	0.6	2
159	FLT3 Inhibitors in the Management of Acute Myeloid Leukemia. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 1028-1032.	0.9	2
160	Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 1974-1974.	0.6	2
161	Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?. <i>Blood Research</i> , 2021, 56, 333-334.	0.5	2
162	OAB-004: Carfilzomib-based induction/consolidation with or without autologous transplant and Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) maintenance: efficacy in high-risk patients of the FORTE study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S3.	0.2	2

#	ARTICLE	IF	CITATIONS
163	The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 115-115.	0.6	2
164	Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma) Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1111-1117.	1.1	2
165	Assessing gene function in human B cells: CRISPR/Cas9-based gene editing and mRNA-based gene expression in healthy and tumor cells. <i>European Journal of Immunology</i> , 2022, 52, 1362-1365.	1.6	2
166	A case of adult acute myelocytic leukemia (M5a) with a near-tetraploid karyotype characterized by monosomies 5 and 16. <i>Cancer Genetics and Cytogenetics</i> , 2004, 150, 88-89.	1.0	1
167	A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2004, 154, 193-194.	1.0	1
168	Trisomy 22 as sole cytogenetic abnormality in acute monoblastic leukemia (M5b). <i>Cancer Genetics and Cytogenetics</i> , 2006, 169, 86.	1.0	1
169	Isolated deletion of 6q in a patient with myelodysplastic syndrome. <i>Cancer Genetics and Cytogenetics</i> , 2009, 192, 51.	1.0	1
170	Hyperlipidemic myeloma. <i>Annals of Hematology</i> , 2010, 89, 939-940.	0.8	1
171	Hyperlipidemia in a myeloma patient after bortezomib treatment. <i>Leukemia Research</i> , 2010, 34, e250.	0.4	1
172	Lenalidomide efficacy in bortezomib-resistant myeloma. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 1-1.	12.5	1
173	Predicting the clinical course of Hodgkin lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 1-1.	12.5	1
174	Unusual localizations of plasmacytoma. <i>Leukemia Research</i> , 2011, 35, e104-e105.	0.4	1
175	Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. <i>Leukemia Research and Treatment</i> , 2012, 2012, 1-4.	2.0	1
176	Treatment of smoldering multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 724-724.	12.5	1
177	Central nervous system multiple myeloma: a different cytogenetic profile. <i>British Journal of Haematology</i> , 2014, 165, 889-890.	1.2	1
178	Oral low-dose fludarabine and cyclophosphamide with rituximab as initial treatment for elderly patients with chronic lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2015, 56, 1916-1917.	0.6	1
179	Central Nervous System Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e133.	0.2	1
180	LONG TERM SAFETY AND EFFICACY OF DARATUMUMAB RAPID INTRAVENOUS INFUSION (90 MINUTES) AFTER THE THIRD DOSE IN MULTIPLE MYELOMA PATIENTS. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e147-e148.	0.2	1

#	ARTICLE	IF	CITATIONS
181	DART4MM: Daratumumab as Consolidation Therapy in Patients who Already Achieved Optimal Response /MRD Positivity by Next Generation Flow (NGF): Preliminary Results of a Phase 2 Multicenter Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e161-e162.	0.2	1
182	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). <i>Haematologica</i> , 2020, 105, 2671-2674.	1.7	1
183	Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1897-1906.	0.6	1
184	Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study. <i>Blood</i> , 2015, 126, 2946-2946.	0.6	1
185	Baseline Thrombophilic Alterations and Risk of Venous Thromboembolism in 266 Multiple Myeloma Patients Primarily Treated with Thalidomide and High-Dose Dexamethasone.. <i>Blood</i> , 2007, 110, 3997-3997.	0.6	1
186	CMLVAX100 Peptide Vaccinations induce Peptide Specific $\alpha\text{œcytotoxic}\alpha\text{€}\cdot\text{CD4}^+$ T Cells (CD4+CTLs) in Chronic Myeloid Leukemia Patients: New Insights about Peptide Vaccine-Mediated Antitumor Response. <i>Blood</i> , 2008, 112, 3209-3209.	0.6	1
187	Central Nervous System and Intracranial Myeloma: a Retrospective Italian Multicenter Study.. <i>Blood</i> , 2009, 114, 1882-1882.	0.6	1
188	Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience. <i>Blood</i> , 2014, 124, 5655-5655.	0.6	1
189	Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. <i>Blood</i> , 2018, 132, 2004-2004.	0.6	1
190	A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in $\text{E}\frac{1}{4}$ -TCL1 mice through the JNK/STAT4/p66Shc axis. <i>Pharmacological Research</i> , 2021, 174, 105965.	3.1	1
191	Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 9-10.	0.4	1
192	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	0.6	1
193	Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Blood</i> , 2021, 138, 1479-1479.	0.6	1
194	Minimal Residual Disease (MRD) at 10-6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment) Tj ETQq0 @OrgBT /Overlock 10		
195	Editorial: Molecular Mechanisms of Multiple Myeloma. <i>Frontiers in Oncology</i> , 2022, 12, 870123.	1.3	1
196	A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05379.	0.2	1
197	Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 92-96.	0.4	1
198	Effect of 5637 conditioned medium (CM) on the mitotic index in the cytogenetic evaluation of myeloproliferative disorders. <i>Annales De GÃ©nÃ©tique</i> , 2004, 47, 432-434.	0.4	0

#	ARTICLE	IF	CITATIONS
199	A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase. <i>Cancer Genetics and Cytogenetics</i> , 2004, 150, 90-91.	1.0	0
200	Trisomy 13 in a patient with idiopathic myelofibrosis. <i>Cancer Genetics and Cytogenetics</i> , 2005, 156, 185.	1.0	0
201	Trisomy 13 in a patient with acute myeloid leukemia M0 and unusual durable remission. <i>Cancer Genetics and Cytogenetics</i> , 2006, 167, 182.	1.0	0
202	Bortezomib and restoration of chemosensitivity. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 1-1.	12.5	0
203	Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia. <i>Cancer Genetics and Cytogenetics</i> , 2010, 197, 84-85.	1.0	0
204	Physicians and end-of-life issues. <i>Cancer</i> , 2010, 116, 3978-3978.	2.0	0
205	Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib. <i>Leukemia Research</i> , 2010, 34, e215-e216.	0.4	0
206	A der(1)t(1;21)(p36.3;q22) in a Patient with Acute Myelogenous Leukemia M2. <i>Acta Haematologica</i> , 2010, 124, 44-45.	0.7	0
207	Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2011, 117, 3530-3530.	2.0	0
208	Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 124-127.	0.4	0
209	LDH as Predictive Parameter in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S213.	0.2	0
210	CLL-251: Venetoclax for CLL Patients Outside Clinical Trials: An Italian Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S225-S226.	0.2	0
211	Evaluation of Ph+/CD34+ Residual Cells in Chronic Myeloid Leukemia Patients after Long Lasting Treatment with Imatinib Mesylate.. <i>Blood</i> , 2005, 106, 1999-1999.	0.6	0
212	Long Term Follow up on Patients with Ph-Abnormal Clones Emerged during Imatinib Therapy.. <i>Blood</i> , 2006, 108, 2116-2116.	0.6	0
213	Zoledronic Acid Early Increases Serum Osteoprotegerin in Early Stage Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3588-3588.	0.6	0
214	The Effects of Zoledronic Acid on Serum Lipids in Multiple Myeloma Patients.. <i>Blood</i> , 2007, 110, 4828-4828.	0.6	0
215	Unfavourable Outcome and Heterogeneity of Partner Chromosomes in Chronic Lymphocytic Leukemia with 14q32/IGH Translocations.. <i>Blood</i> , 2007, 110, 4686-4686.	0.6	0
216	Two Novel WT-1 Derived Peptides Induce CD4+ peptide-specific T Cell Proliferation in Patients with Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2008, 112, 5432-5432.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 65 Ys: Response and Follow-up of 84 Patients.. Blood, 2009, 114, 4147-4147.	0.6	0
218	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 3578-3578.	0.6	0
219	Molecular Cytogenetics Analysis of 13q14 Biallelic Deletion in Chronic Lymphocytic Leukemia: A Study on 250 Patients. Blood, 2011, 118, 1454-1454.	0.6	0
220	Efficacy and Safety Of Bendamustine In Combination With Rituximab For Elderly Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. A Retrospective Multicenter Study. Blood, 2013, 122, 5309-5309.	0.6	0
221	Combined Use of Growth Factors to Stimulate the Proliferation of Hematopoietic Progenitor Cells after Autologous Bone Marrow Transplantation (ABMT) for Lymphoma Patients. , 1996, , 11-20.		0
222	Evolving Treatments in Multiple Myeloma Patients with Renal Failure. Reviews on Recent Clinical Trials, 2015, 9, 276-279.	0.4	0
223	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood, 2016, 128, 3276-3276.	0.6	0
224	A Distributed International Patient Data Registry for Hairy Cell Leukemia. Blood, 2016, 128, 5986-5986.	0.6	0
225	Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region. Farmeconomia E Percorsi Terapeutici, 2020, 21, .	0.2	0
226	Commentary. Journal of Neurosciences in Rural Practice, 2013, 4, 448.	0.3	0
227	Monoclonal Gammopathy of Ocular Significance (MGOS) - a Series of Corneal Manifestations and Treatment Outcomes. Blood, 2021, 138, 2695-2695.	0.6	0
228	Chronic Lymphocytic Leukemia (CLL) Patients Quality of Life (QoL): A Cross-Sectional Analysis of the Italian Experience in the Choice Study during the First Wave of the COVID-19 Pandemic. Blood, 2021, 138, 4680-4680.	0.6	0
229	Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes with Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients with Chronic Lymphocytic Leukemia from Senegal. Blood, 2020, 136, 19-19.	0.6	0
230	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. Blood, 2020, 136, 23-25.	0.6	0
231	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. Blood, 2020, 136, 30-31.	0.6	0